Trials / Unknown
UnknownNCT04556292
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
A Phase 2, Open-Label, Multi-Center Study of SC10914 in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received More Than 2 Prior Chemotherapy Regimens for Metastatic Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open label, multi-centre phase II study will assess the efficacy and safety of single agent SC10914 in metastatic breast cancer patients with gBRCA 1/2 mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SC10914 | SC10914 400mg tid |
Timeline
- Start date
- 2020-08-12
- Primary completion
- 2022-03-30
- Completion
- 2022-08-30
- First posted
- 2020-09-21
- Last updated
- 2020-09-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04556292. Inclusion in this directory is not an endorsement.